Loading…
Loading…
DENVER, July 15, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced that the Board of Directors of Antero Midstream declared a cash dividend of $0.225 per share for the second quarter of 2026. The Company also repurchased approximately 0.4 million shares during the second quarter.
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).
The energy sector is the top performer this year, but investors shouldn't forget the group's attractive dividend profile.
AM's Q1 revenues top estimates on strong volumes, but rising costs weigh on earnings despite robust gathering and compression growth.
Antero Midstream generated $288 million in Q1 2026 adjusted EBITDA with a partial quarter contribution from its HG Midstream acquisition. It expects roughly $309 million per quarter in adjusted EBITDA during the rest of the year. Future growth results in a projected $1.4 billion in 2028 adjusted EBITDA in a base case scenario and $1.5 billion in an upside scenario.
Antero Midstream Corporation (AM) Q1 2026 Earnings Call Transcript
Antero Midstream now guides for single-digit growth. AM's stock price has risen substantially since 2020. That rise has pushed valuation metrics, including a P/E ratio nearing 20, to uncomfortable highs. Current pricing exposes investors to downside risk relative to historical valuation norms.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for AM and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.